- Home
- CPT vs GMAB Comparison
CPT vs GMAB Comparison
Compare CPT & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPT
- GMAB
- Stock Information
- Founded
- CPT 1993
- GMAB 1999
- Country
- CPT United States
- GMAB Denmark
- Employees
- CPT N/A
- GMAB N/A
- Industry
- CPT Real Estate Investment Trusts
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CPT Real Estate
- GMAB Health Care
- Exchange
- CPT Nasdaq
- GMAB Nasdaq
- Market Cap
- CPT 12.2B
- GMAB 12.1B
- IPO Year
- CPT 1993
- GMAB N/A
- Fundamental
- Price
- CPT $119.84
- GMAB $22.34
- Analyst Decision
- CPT Buy
- GMAB Buy
- Analyst Count
- CPT 20
- GMAB 9
- Target Price
- CPT $125.48
- GMAB $40.71
- AVG Volume (30 Days)
- CPT 917.9K
- GMAB 1.9M
- Earning Date
- CPT 02-06-2025
- GMAB 02-12-2025
- Dividend Yield
- CPT 3.50%
- GMAB N/A
- EPS Growth
- CPT N/A
- GMAB 83.82
- EPS
- CPT 1.50
- GMAB 16.85
- Revenue
- CPT $1,555,399,000.00
- GMAB $2,988,286,182.00
- Revenue This Year
- CPT N/A
- GMAB $18.78
- Revenue Next Year
- CPT $3.96
- GMAB $14.98
- P/E Ratio
- CPT $79.93
- GMAB $12.94
- Revenue Growth
- CPT 0.58
- GMAB 30.67
- 52 Week Low
- CPT $92.26
- GMAB $18.64
- 52 Week High
- CPT $127.69
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- CPT 60.42
- GMAB 65.39
- Support Level
- CPT $117.56
- GMAB $18.74
- Resistance Level
- CPT $121.50
- GMAB $22.55
- Average True Range (ATR)
- CPT 2.43
- GMAB 0.46
- MACD
- CPT 0.44
- GMAB 0.39
- Stochastic Oscillator
- CPT 83.53
- GMAB 94.64
About CPT Camden Property Trust
Camden Property Trust is a real estate investment trust primarily engaged in the acquisition, management, and development of multifamily apartment communities across the United States. The company's real estate portfolio consists primarily of apartment properties throughout the Sun Belt. Houston, Dallas, Las Vegas, and Atlanta represent some of Camden's largest housing markets in terms of apartment units. The firm derives nearly all of its revenue from the leasing of properties to tenants through short-term agreements. Camden Property derives the majority of its revenue from the Washington D.C., Los Angeles, Houston, Atlanta, and southeastern Florida areas.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.